A new vaccine using the same mRNA technology as the Pfizer jab against COVID-19 could be a breakthrough in the fight against pancreatic cancer.In a promising early study conducted by German company BioNTech — which partnered with Pfizer to develop the lifesaving COVID shot — half of the patients remained cancer-free 18 months after having their tumors removed and receiving the jabs. The groundbreaking trial — led by Dr. Vinod Balachandran at the Memorial Sloan Kettering Cancer Center in Manhattan — presented its promising results at the American Society of Clinical Oncology conference in Chicago on Sunday.
Load More
Load More